HotSpot Therapeutics is a technology company.
HotSpot Therapeutics has raised $210.0M across 3 funding rounds.
HotSpot Therapeutics has raised $210.0M in total across 3 funding rounds.
HotSpot Therapeutics is a clinical-stage biotechnology company developing oral, small-molecule allosteric therapies that target "natural hotspots"—regulatory sites on proteins—to address undruggable targets in cancer and autoimmune diseases.[1][2][5] Its proprietary Smart Allostery™ platform combines AI-driven data mining, computational approaches, and bespoke chemistry to identify these hotspots and design selective inhibitors, such as HST-1011 (a CBL-B inhibitor) and programs targeting IRF5, serving pharmaceutical needs for novel oncology and immunology treatments.[1][2][6] The company demonstrates strong growth momentum, with Phase 1 clinical data presentations in 2024 and a pipeline advancing toward transformative therapies.[1]
HotSpot Therapeutics was founded in 2016 or 2017 in Boston, Massachusetts, by co-founders who had previously developed hotspot regulatory binders at other biotech firms and saw the need for a systematic platform to exploit these sites.[1][3][7] The idea emerged from recognizing nature's finely tuned protein control mechanisms—regulatory hotspots—that could enable small-molecule drugs for previously undruggable proteins, inspired by gaps in traditional drug discovery.[5][7] Early traction came from assembling a team of scientists with drug discovery expertise, securing funding from leading US and European healthcare investors like EQT's LSP 7 fund, and rapidly building a pipeline, including pioneering the first selective CBL-B inhibitor.[2][4][7]
HotSpot rides the wave of precision oncology and immunotherapy evolution, building on milestones like the first precision therapies 20 years ago and immune therapies a decade ago, by pioneering allosteric modulation of immune-regulating proteins like CBL-B to enhance T-cell responses.[1][2] Timing aligns with surging demand for novel modalities amid stalled traditional targets, fueled by AI/biotech convergence that unlocks undruggable proteins—market forces like rising autoimmune/cancer prevalence and investor interest in differentiated pipelines amplify this.[2][5][9] The company influences the ecosystem by redefining drug discovery, inspiring systematic hotspot targeting, and contributing to Boston's biotech hub through talent attraction and clinical advancements.[3][7]
HotSpot is poised for pipeline expansion, with HST-1011 Phase 1 data at SITC 2024 signaling near-term milestones like full clinical readouts and potential INDs for IRF5 and other programs.[1][2] Trends in AI-enabled drug design and allosteric therapies will accelerate its momentum, potentially positioning it as a leader in transforming immune-oncology and autoimmunity treatments. As it scales from clinical-stage to approvals, HotSpot's unwavering focus on hotspots and human-centered values could redefine biotech innovation, delivering on its promise to drug the undruggable and impact millions.
HotSpot Therapeutics has raised $210.0M in total across 3 funding rounds.
HotSpot Therapeutics's investors include AbbVie Ventures, Access Biotechnology, Atlas Venture, EQT Life Sciences, Novo Ventures, Pivotal bioVenture Partners, RiverVest, Roche Venture Fund, Samsara BioCapital, Soffinova Partners, SR One.
HotSpot Therapeutics has raised $210.0M across 3 funding rounds. Most recently, it raised $100.0M Series C in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $100.0M Series C | AbbVie Ventures, Access Biotechnology, Atlas Venture, EQT Life Sciences, Novo Ventures, Pivotal bioVenture Partners, RiverVest, Roche Venture Fund, Samsara BioCapital, Soffinova Partners, SR One | |
| May 1, 2020 | $65.0M Series B | AbbVie Ventures, Access Biotechnology, Atlas Venture, Novo Ventures, RiverVest, Roche Venture Fund, Soffinova Partners, SR One | |
| Jul 1, 2018 | $45.0M Series A | AbbVie Ventures, Access Biotechnology, Atlas Venture, Roche Venture Fund, Soffinova Partners |